PROGNOSTIC VALUE OF ELEVATED LIPOPROTEIN (A) CONCENTRATION TO PREDICT ATHEROSCLEROTIC CARDIOVASCULAR DISEASE IN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS

被引：0
|
作者：
Shishikura, Daisuke [1 ]
Harada-Shiba, Mariko [1 ]
Fujisaka, Tomohiro [1 ]
Morita, Hideaki [1 ]
Kanzaki, Yumiko [1 ]
Hoshiga, Masaaki [1 ]
机构：
[1] Osaka Med & Pharmaceut Univ, Cardiol, Takatsuki, Osaka, Japan
来源：
ATHEROSCLEROSIS | 2024年 / 395卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SaaG054
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Equivalent Impact of Elevated Lipoprotein(a) and Familial Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease
    Hedegaard, Berit Storgaard
    Bork, Christian Sorensen
    Kaltoft, Morten
    Klausen, Ib Christian
    Schmidt, Erik Berg
    Kamstrup, Pia Rorbaek
    Langsted, Anne
    Nordestgaard, Borge Gronne
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 80 (21) : 1998 - 2010
  • [2] Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE)
    Sudano, Isabella
    Mach, Francois
    Moccetti, Tiziano
    Burkard, Thilo
    Fahe, Christian
    Delabays, Alain
    Rickli, Hans
    Keller, Pierre-Frederic
    Dopheide, Jorn
    Bodenmann, Sereina
    Fiolka, Tom
    Ehret, Georg
    Spirk, David
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [3] Optimized treatment of refractory hypercholesterolemia in patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia with alirocumab (OPTIMIZE)
    Sudano, I.
    Mach, F.
    Mocetti, T.
    Burkard, T.
    Fahe, C.
    Delabays, A.
    Rickli, H.
    Keller, P. F.
    Dopheide, J.
    Bodenmann, S.
    Fiolka, T.
    Ehret, G.
    Spirk, D.
    SWISS MEDICAL WEEKLY, 2022, 152 : 23S - 23S
  • [4] Effect of causative genetic variants on atherosclerotic cardiovascular disease in heterozygous familial hypercholesterolemia patients
    Matta, Anthony
    Rabes, Jean Pierre
    Taraszkiewicz, Dorota
    Carrie, Didier
    Roncalli, Jerome
    Ferrieres, Jean
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2023, 10
  • [5] Lipoprotein(a) is an independent risk factor for cardiovascular disease in heterozygous familial hypercholesterolemia
    Holmes, DT
    Schick, BA
    Humphries, KH
    Frohlich, J
    CLINICAL CHEMISTRY, 2005, 51 (11) : 2067 - 2073
  • [6] LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVELS AMONG PATIENTS WITH CLINICAL ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA POST STATIN THERAPY
    Johnson, B. H.
    Bonafede, M. M.
    Princic, N.
    Harrison, D. J.
    Boatman, B.
    Patel, J.
    VALUE IN HEALTH, 2016, 19 (03) : A58 - A58
  • [7] Lipoprotein(a) metabolism in patients with heterozygous familial hypercholesterolemia
    Parhofer, KG
    Ritter, MM
    Geiss, C
    Schwandt, P
    ATHEROSCLEROSIS, 1997, 134 (1-2) : 146 - 146
  • [8] PREVALENCE OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN PATIENTS WITH ESTABLISHED ATHEROSCLEROTIC DISEASE IN THE COLOMBIAN NORTHEAST
    Delgado, E. N.
    Parra Serrano, G. A.
    Lindarte, H. H.
    Vesga, B.
    Serrano-Gomez, S.
    ATHEROSCLEROSIS, 2020, 315 : E215 - E215
  • [9] COMBINED TREATMENT WITH SIMVASTATIN AND ACIPIMOX IN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA WITH ELEVATED LIPOPROTEIN(A)
    MULS, E
    BEX, M
    COBBAERT, C
    VANSANT, G
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 1994, 4 (02) : 78 - 82
  • [10] Relation of Serum Lipoprotein(a) Levels to Lipoprotein and Apolipoprotein Profiles and Atherosclerotic Diseases in Japanese Patients with Heterozygous Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study
    Naito, Ryo
    Daida, Hiroyuki
    Masuda, Daisaku
    Harada-Shiba, Mariko
    Arai, Hidenori
    Bujo, Hideaki
    Ishibashi, Shun
    Koga, Nobuhiko
    Oikawa, Shinichi
    Yamashita, Shizuya
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2022, 29 (08) : 1188 - 1200
12345